SAN DIEGO, November 18, 2019 – Imbria Pharmaceuticals, Inc. today announced that Imbria Pharmaceuticals will present at the Stifel 2019 Healthcare Conference on Wednesday, November 20, 2019 at 8:35 am ET at the Lotte New York Palace Hotel, New York, NY. David-Alexandre C. Gros, M.D., President and Chief Executive Officer, and Heidi Henson, Chief Financial Officer, will present at the conference.
About Imbria Pharmaceuticals
Imbria Pharmaceuticals uses our deep understanding of cellular energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. Our lead program, IMB-101, is currently in Phase 1 clinical development, and will be further developed for two separate indications: refractory angina and heart failure. Additional product candidates, IMB-202 and IMB-203, are designed to address cellular energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism. For additional information, please visit www.imbria.com.